Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 15/3/2021
SIETES contiene 93212 citas

 1 a 13 de 13 
Presentar resultados
Seleccionar todas
1. Cita con resumen
Shardlow A, McIntyre NJ, Fraser SDS, Roderick P, Raftery J, Fluck RJ, McIntyre CW, Taal MW. The clinical utility and cost impact of cystatin C measurement in the diagnosis and management of chronic kidney disease: A primary care cohort study. PLOS Medicine 2017:10 de octubre. [Ref.ID 102114]
2. Cita con resumen
Limdi NA, Nolin TD, Booth SL, Centi A, Marques MB, Crowley MR, Allon M, Beasley TM. Influence of kidney function on risk of supratherapeutic international normalized ratio-related hemorrhage in warfarin users: a prospective cohort study. Am J Kidney Dis 2015;65:701-9. [Ref.ID 99105]
4. Cita con resumen
Amet S, Zimner-Rapuch S, Launay-Vacher V, Janus N, Deray G. Malaria prophylaxis in patients with renal impairment. A review. Drug Saf 2013;36:83-91. [Ref.ID 94863]
5.Tiene citas relacionadas Cita con resumen
Aspinall SL, Cunningham FE, Zhao X, Boresi JS, Tonnu-Mihara IQ, Smith KJ, Stone RA, Good CB, ESA Clinic Study Group. Impact of pharmacist-managed erythropoiesis - Stimulating agents clinics for patients with non-dialysis-dependent CKD. Am J Kidney Dis 2012;60:371-9. [Ref.ID 92943]
6. Cita con resumen
Anónimo. Liraglutide (Victoza) for type 2 diabetes. Med Lett Drugs Ther 2010;52:25-7. [Ref.ID 88429]
7. Cita con resumen
Iorio A, Basileo M, Marcucci M, Guercini F, Camilloni B, Paccamiccio E, Vecchioli M, Iorio A. Influenza vaccination and vitamin K antagonist treatment. A placebo-controlled, randomized, double-blind crossover study. Arch Intern Med 2010;170:609-16. [Ref.ID 88295]
Mehuys E, Kayitare E, Vervaet C, Remon J-P. Adjustment of dosing of antimicrobial agents for bodyweight in adults. Lancet 2010;375:983-4. [Ref.ID 88164]
Anónimo. Body surface area for adjustment of drug dose. Drug Ther Bull 2010;48:33-6. [Ref.ID 88037]
10. Cita con resumen
Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide — The FDA’s review of a new antidiabetic therapy. N Engl J Med 2010;362:774-7. [Ref.ID 87929]
11. Cita con resumen
Naughton C. Drug-induced nephrotoxcicity. American Family Physician 2008;78:743-50. [Ref.ID 87065]
12.Enlace a cita original
Verbeeck RK, Musuamba FT. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol 2009;65:757-73. [Ref.ID 86605]
Schlatter C, Egger SS, Tchambaz L, Krähenbühl S. Pharmacokinetic changes of psychotropic drugs in patients with liver disease: implications for dose adaptation. Drug Saf 2009;32:561-78. [Ref.ID 86467]
Seleccionar todas
 1 a 13 de 13